New research by neurologists at the University at Buffalo has shown that a technique called optical coherence tomography, a simple and inexpensive measure employed currently to assess glaucoma, also could be used as a surrogate marker of disease status in multiple sclerosis (MS) and to assess the effectiveness of new and current MS treatments.